|
Hersteller |
Cell Sciences |
|
Kategorie |
|
|
Typ |
Proteins |
|
Specific against |
Human |
|
Menge |
100 ug |
|
Host |
CHO cells |
|
ArtNr |
CS-CRCC02 |
|
Eclass 6.1 |
34160400 |
|
Eclass 9.0 |
42020190 |
|
Lieferbar |
 |
| Description |
Recombinant human CD14 is produced from human CD14 transfected CHO cells. Before transfection the complete human CD14-cDNA was amplified by PCR and cloned into expression vector p-POL-DHFR. The dominant form of the recombinant wild type CD14 is the 50 kDa protein. The myeloid differentiation antigen CD14 acts as the major receptor for bacterial LPS. CD14 has been shown to be involved in the LPS-induced cell activation. This antigen is present as a membrane bound form and soluble antigen, both involved in cell stimulation by LPS. The plasma protein LBP plays an important role in this LPS-CD14 mediated cell activation. Monocytes and PMN are activated by the LBP-LPS complex via membrane CD14. |
| Formulation |
Lyophilized from serum free culture supernatant of CHO transfectants (CHO-S-SFM-II + antibiotics, without sodium azide). |
| Reconstitution |
Centrifuge vial prior to opening. Add 100 ul sterile distilled water to the vial to fully solubilize the protein to a concentration of 1.0 mg/ml. |
| Storage and Stability |
Store in working aliquots at -80C. Avoid repeated freeze-thaw cycles. |
| Source |
CHO cells |
| Molecular Weight |
50 kDa |
| Biological Activity |
50 ug/ml totally inhibits binding of FITC-LPS (0.5 ug/ml) to 6 x 105 CD14+CHO transfectants. Up to 10 ug/ml inhibits binding of LPS-FITC. |
